Costs associated with adverse events for systemic therapies in metastatic melanoma.

9560Background: Current systemic therapies of metastatic melanoma (MM) include immunotherapy, target therapy (if BRAF mutated), high-dose IL-2, and chemotherapy, all of which are associated with di...